Denver-based market research startup GutCheck has found $4 million for a Series B round of financing.
Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.
Conatus Pharmaceuticals has joined a long line of drug developers seeking to go public. The San Diego-based company, which has a lead drug candidate acquired from Pfizer, revealed plans on Friday to complete an initial public offering of up to $69 million.
It is Pfizer that will get another chance to knock down an Alabama Supreme Court ruling on the safety of generic drugs, but it stands in for the entire drug development industry that wants to see the the ruling reversed.
Pfizer believes it has a winner with Eliquis. It has the right market niche, a replacement for blood thinner warfarin, and the clinical data that should make it a star. What it hasn't had so far is a fast start toward bigtime sales.
Will Pfizer's big patent win against Teva Pharmaceutical Industries and India's Sun Pharma on Protonix discourage more "at-risk" drug launches of generics in the U.S.?
A new AARP study worries that Pfizer's aggressive use of price hikes, pay-for-delay deals, and discounts and coupons when Lipitor faced generic competition will become the blueprint for the industry.
When Teva Pharmaceutical Industries launched a generic version of Protonix in 2007 before its patent expiration, it set aside $670 million to compensate Pfizer for lost profits on the drug. But with a settlement announced today, the company is finding itself $1.6 billion short.
Pfizer is partnering up with South San Francisco-based CytomX Therapeutics on a discovery program, putting the biotech's R&D platform to work on finding some next-gen antibody-drug conjugates for cancer targets.
Just as the situation for Big Pharma in India seemed its most dour, what with intellectual-property disputes and controversial price caps, India's Intellectual Property Appellate Board may have thrown Pfizer a bone. It has gone back on last year's decision--for now--to revoke the patent for Pfizer's cancer drug Sutent.